Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort

Stefano Gentileschi,Carla Gaggiano,Arianna Damiani,Carmela Coccia,Pamela Bernardini,Massimiliano Cazzato, Francesco D’Alessandro, Giulia Vallifuoco, Riccardo Terribili,Marco Bardelli,Caterina Baldi,Luca Cantarini,Marta Mosca,Bruno Frediani,Serena Guiducci

Clinical and Experimental Medicine（2024）

引用 0|浏览3

暂无评分

摘要

Inhibiting Janus Kinases (JAK) is a crucial therapeutic strategy in rheumatoid arthritis (RA). However, the use of JAK inhibitors has recently raised serious safety concerns. The study aims to evaluate the safety profile of JAKi in patients with RA and identify potential risk factors (RFs) for adverse events (AEs). Data of RA patients treated with JAKi in three Italian centers from January 2017 to December 2022 were retrospectively analyzed. 182 subjects (F:117, 64.3

查看译文

关键词

Rheumatoid arthritis,JAK inhibitors,Safety,Cardiovascular risk factors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要